Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Treasury Shares (2016 - 2026)

Avanos Medical's Treasury Shares history spans 11 years, with the latest figure at $102.3 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 3.33% to $102.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $102.3 million, a 3.33% increase, with the full-year FY2025 number at $102.3 million, up 3.33% from a year prior.
  • Treasury Shares hit $1.0 million in Q4 2025 for Avanos Medical, down from $3.7 million in the prior quarter.
  • Over the last five years, Treasury Shares for AVNS hit a ceiling of $3.7 million in Q4 2024 and a floor of $169571.0 in Q2 2024.
  • Historically, Treasury Shares has averaged $1.0 million across 5 years, with a median of $743000.0 in 2023.
  • Biggest five-year swings in Treasury Shares: surged 538.46% in 2022 and later rose 3.13% in 2025.
  • Tracing AVNS's Treasury Shares over 5 years: stood at $21.3 million in 2021, then skyrocketed by 213.62% to $66.8 million in 2022, then grew by 28.59% to $85.9 million in 2023, then increased by 15.25% to $99.0 million in 2024, then grew by 3.33% to $102.3 million in 2025.
  • Business Quant data shows Treasury Shares for AVNS at $102.3 million in Q4 2025, $102.0 million in Q3 2025, and $101.9 million in Q2 2025.